LinkedIn Profile

Access Definigen historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:definigen 3748917 Dec 3rd, 2020 12:00AM DefiniGEN 687 15.00 Open Biotechnology Dec 3rd, 2020 09:51AM Dec 3rd, 2020 09:51AM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Dec 2nd, 2020 12:00AM DefiniGEN 686 15.00 Open Biotechnology Dec 2nd, 2020 12:12PM Dec 2nd, 2020 12:12PM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Dec 1st, 2020 12:00AM DefiniGEN 685 15.00 Open Biotechnology Dec 1st, 2020 10:45AM Dec 1st, 2020 10:45AM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 30th, 2020 12:00AM DefiniGEN 683 15.00 Open Biotechnology Nov 30th, 2020 12:50PM Nov 30th, 2020 12:50PM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 29th, 2020 12:00AM DefiniGEN 683 15.00 Open Biotechnology Nov 29th, 2020 05:49PM Nov 29th, 2020 05:49PM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 28th, 2020 12:00AM DefiniGEN 682 15.00 Open Biotechnology Nov 28th, 2020 01:41PM Nov 28th, 2020 01:41PM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 27th, 2020 12:00AM DefiniGEN 681 15.00 Open Biotechnology Nov 27th, 2020 10:02AM Nov 27th, 2020 10:02AM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 26th, 2020 12:00AM DefiniGEN 677 15.00 Open Biotechnology Nov 26th, 2020 11:02AM Nov 26th, 2020 11:02AM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 25th, 2020 12:00AM DefiniGEN 673 15.00 Open Biotechnology Nov 25th, 2020 02:01PM Nov 25th, 2020 02:01PM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology
private:definigen 3748917 Nov 24th, 2020 12:00AM DefiniGEN 671 15.00 Open Biotechnology Nov 24th, 2020 11:12AM Nov 24th, 2020 11:12AM DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company’s key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke’s Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments. Open Induced Pluripotent Stem Cells (iPSC), Hepatocytes, Pancreatic Cells, Disease Modelling, Drug Discovery, Toxicity testing, Inherited Metabolic Diseases (IMD) Open Babraham Research Campus, Babraham Cambridge GB CB22 3AT Definigen Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.